Pharmaceuticals, Biotechnology and Life Sciences
– Progressing our lead program, AB928, a potential best-in-class dual A2a/A2b receptor antagonist, into multiple dose-expansion cohorts in 2H19, including…
IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. has released its July 2019 Drug Price Forecast projecting health systems, including inpatient and non-acute environments,…
PARIS–(BUSINESS WIRE)–#TREM1–Inotrem S.A., a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, announced today the U.S. Food and Drug…
NEW YORK–(BUSINESS WIRE)–Schrödinger today announced the appointment of veteran pharmaceutical executive Gary Sender to its Board of Directors, as well…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion…
Telix Pharmaceuticals and German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) have agreed to work together in the field of image-guided surgery for prostate cancer.
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge…
Mylan’s second quarter performance was strong as the company has delivered or exceeded on expectations across all financial metrics, the company’s CEO Heather Bresch said in a press release Monday.
Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%